Skip Navigation

Paul G. Richardson, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center
  • Institute Physician
  • RJ Corman Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Experimental therapeutics and cancer pharmacology
  • Multiple myeloma
  • Non-myeloid injury including VOD in bone marrow transplantation
  • Regimen-related toxicity
  • Stem cell transplantation

Diseases Treated

Contact Information

  • Appointments617-632-3823 (new)
    617-632-2127 (follow-up)
  • Office Phone Number617-632-2127
  • Fax617-632-6624

Bio

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma. Subsequent studies have focused on next-generation novel drugs including panobinostat and second-generation proteasome inhibitors including ixazomib. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and an first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma.

Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD. This regimen has generated an unprecedented response rate, leading to its adoption in this international study, as well as others in the United States and elsewhere. This particular trial incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy and the optimal positioning of stem cell transplant, with results anticipated in 2021-22. Furthermore, RVD has been established as a backbone to which next-generation agents are being added, including elotuzumab, daratumumab and isatuximab, as well as panobinostat.

He has published extensively, having authored or co-authored over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role.

Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well as an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple Myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway in 2012. He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by the second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. He was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the prestigious IMF Robert A. Kyle Lifetime Achievement Award in 2017, and the Morse Research Award in 2019.

Board Certification:

  • Hematology, 1999
  • Internal Medicine, 1997
  • Medical Oncology, 1998

Fellowship:

  • Baystate Medical Center, Tufts University, Hematology & Oncology

Residency:

  • Beth Israel Deaconess Medical Center, Internal Medicine
  • Newcastle General and Freeman Hospitals, Internal Medicine
  • Royal Marsden Hospital, London, Chief Resident

Medical School:

  • University of London, St. Bartholomew's Medical College

Recent Awards:

  • Biochemistry Slot Prize, Hungarian Prize, Honours Colors, Wheelwrights Prize, Ver Heyden de Lancy Prize: Joint Winner, Emil Frei III Fellowship Award, Lee Beckenstein Fellowship Award, The Society of Teaching Scholars, George Canellos Award for Excellence in Clinical Research and Patient Care, Partners in Excellence Award, Medical Book Competition Award for Multiple Myeloma, Tisch Family Outstanding Achievement Award in Translational Research, Compassionate Caregiver Award, Fellow of the Royal College of Physicians 1983 1986 1986 1986 1986 1995 1997 2002 2004 2004,2005 2005 2008 2008 2009

Research

Research in Multiple Myeloma, Reduction of Regimen-Related Toxicity

Under the overall direction and mentorship of Dr. Kenneth Anderson, we are leading several translational efforts in multiple myeloma, including phase I, II, and III clinical trials of new drugs: thalidomide, the thalidomide analog IMiD 3 (also known as lenalidomide, CC-5013, or Revlimid), 2- methoxy estradiol (2-ME2), and the proteasome inhibitor PS 341 (bortezomib or Velcade). Subsequent studies have focused on other novel agents including the histone deacetylase inhibitor SAHA and derivatives of the HSP-90 inhibitor 17-AAG, as well as other small molecules. Our most recent translational research is a phase I trial of the combination of novel agents lenalidomide and bortezomib. In addition to research in myeloma, we have been involved in regimen-related toxicities (RRT), and in particular the development of defibrotide as a novel therapy for hepatic veno-occlusive disease. This work has led to further research in syndromes characterized by endothelial cell injury during high-dose therapy and the study of vascular damage affecting other organ structures, including mucosa. Another important new area of interest in RRT is treatment-emergent neuropathy in myeloma.

Reply to G. R. Mohyuddin et al and A. Garfall et al. J Clin Oncol. 2021 Oct 15; JCO2102081.
View in: PubMed

The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. Bone Marrow Transplant. 2021 Sep 28.
View in: PubMed

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021 Sep 24.
View in: PubMed

Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Am J Hematol. 2021 Nov 01; 96(11):E423-E427.
View in: PubMed

Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncol. 2021 Sep 15.
View in: PubMed

Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res. 2021 Sep 13.
View in: PubMed

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. Eur J Haematol. 2021 Sep 08.
View in: PubMed

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer. 2021 Sep 06; 21(1):993.
View in: PubMed

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 08 12; 385(7):595-608.
View in: PubMed

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2021 Jul 21.
View in: PubMed

Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Rev Hematol. 2021 Aug; 14(8):697-706.
View in: PubMed

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. Am J Hematol. 2021 10 01; 96(10):E383-E386.
View in: PubMed

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol. 2021 09 01; 96(9):1120-1130.
View in: PubMed

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021 Jul 01; 137(26):3616-3628.
View in: PubMed

Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Jun 26.
View in: PubMed

Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin Ther Targets. 2021 06; 25(6):423-433.
View in: PubMed

Distinctive Biomarker Features in The Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2021 Jun 24.
View in: PubMed

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021 Aug 01; 39(22):2430-2442.
View in: PubMed

Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications? Cardiovasc Drugs Ther. 2021 Jun 07.
View in: PubMed

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun; 7(23).
View in: PubMed

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 May 28.
View in: PubMed

Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021 Jul; 194(1):120-131.
View in: PubMed

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol. 2021 06 01; 96(6):708-718.
View in: PubMed

Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply. Lancet. 2021 05 01; 397(10285):1621-1623.
View in: PubMed

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep; 2(5):468-483.
View in: PubMed

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. J Hematol Oncol. 2021 04 13; 14(1):59.
View in: PubMed

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2021 04 01; 106(4):1182-1187.
View in: PubMed

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leuk Res. 2021 05; 104:106576.
View in: PubMed

The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. Br J Haematol. 2021 04; 193(2):213-215.
View in: PubMed

Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation - a case series. Br J Haematol. 2021 05; 193(4):e36-e38.
View in: PubMed

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 Aug; 194(3):496-507.
View in: PubMed

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2021 03 12; 11(3):55.
View in: PubMed

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021 06; 17(16):1987-2003.
View in: PubMed

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
View in: PubMed

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021 02 23; 5(4):1092-1096.
View in: PubMed

Molecular dynamics of targeting CD38 in multiple myeloma. Br J Haematol. 2021 05; 193(3):581-591.
View in: PubMed

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Rev. 2021 09; 49:100808.
View in: PubMed

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib?+?dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer J. 2021 02 05; 11(2):20.
View in: PubMed

COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol. 2021 04; 193(1):43-51.
View in: PubMed

A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021 02 04; 11(2):23.
View in: PubMed

Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). AIDS Res Hum Retroviruses. 2021 03; 37(3):173-183.
View in: PubMed

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. Br J Haematol. 2021 06; 193(6):1105-1109.
View in: PubMed

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021 01 05; 34(1):108532.
View in: PubMed

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021 Jan; 8(1):e45-e54.
View in: PubMed

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767.
View in: PubMed

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021 01; 22(1):142-154.
View in: PubMed

Isatuximab for the treatment of relapsed/refractory multiple myeloma. Expert Opin Biol Ther. 2020 12; 20(12):1395-1404.
View in: PubMed

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
View in: PubMed

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 11 14; 396(10262):1563-1573.
View in: PubMed

Current antibody-based therapies for the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2020 Nov; 18(11):736-748.
View in: PubMed

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020 10 23; 10(10):106.
View in: PubMed

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 01; 96(1):E5-E8.
View in: PubMed

Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when? Aliment Pharmacol Ther. 2020 10; 52(8):1414-1415.
View in: PubMed

Melflufen for relapsed and refractory multiple myeloma. Expert Opin Investig Drugs. 2020 Oct; 29(10):1069-1078.
View in: PubMed

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. J Clin Med. 2020 Sep 27; 9(10).
View in: PubMed

Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 01; 27(1):88.e1-88.e6.
View in: PubMed

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 2021 06; 35(6):1722-1731.
View in: PubMed

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 09 04; 10(9):91.
View in: PubMed

Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020 09 01; 85(1):93-97.
View in: PubMed

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 10; 21(10):1317-1330.
View in: PubMed

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945.
View in: PubMed

Proteasome inhibition for the treatment of glioblastoma. Expert Opin Investig Drugs. 2020 Oct; 29(10):1133-1141.
View in: PubMed

Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 12; 20(12):797-803.
View in: PubMed

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
View in: PubMed

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in: PubMed

The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol. 2020 12; 191(5):692-703.
View in: PubMed

Alcohol-related brain injury: An unrecognized problem in acute medicine. Alcohol. 2020 11; 88:49-53.
View in: PubMed

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020 07; 7(7):e472-e481.
View in: PubMed

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun; 7(6):e447-e455.
View in: PubMed

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-?B pathway activation. Eur J Haematol. 2020 Sep; 105(3):274-285.
View in: PubMed

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021 02; 35(2):562-572.
View in: PubMed

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
View in: PubMed

Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. Cancer Sci. 2020 Jun; 111(6):2116-2122.
View in: PubMed

Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biol Blood Marrow Transplant. 2020 08; 26(8):1414-1424.
View in: PubMed

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J Haematol. 2020 Jul; 105(1):35-46.
View in: PubMed

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leuk Lymphoma. 2020 08; 61(8):1850-1859.
View in: PubMed

Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine. 2020 Apr; 21:100303.
View in: PubMed

Defibrotide formulations contain (1?3)-ß-D-glucan that could influence clinical diagnostic testing. Bone Marrow Transplant. 2020 10; 55(10):2045-2046.
View in: PubMed

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020 May; 7(5):e395-e407.
View in: PubMed

Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. Biol Blood Marrow Transplant. 2020 07; 26(7):1342-1349.
View in: PubMed

Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. Br J Haematol. 2020 08; 190(4):583-587.
View in: PubMed

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol. 2020 04; 13(4):421-433.
View in: PubMed

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clin Lymphoma Myeloma Leuk. 2020 06; 20(6):351-357.
View in: PubMed

Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J. 2020 03 04; 10(3):29.
View in: PubMed

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453.
View in: PubMed

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? Cells. 2020 02 06; 9(2).
View in: PubMed

Selinexor for the treatment of multiple myeloma. Expert Opin Pharmacother. 2020 Mar; 21(4):399-408.
View in: PubMed

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 02; 21(2):207-221.
View in: PubMed

Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020 Jan; 7(1):e61-e72.
View in: PubMed

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplant. 2019 Dec; 54(12):2117-2119.
View in: PubMed

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 12 07; 394(10214):2096-2107.
View in: PubMed

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539.
View in: PubMed

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin Cancer Res. 2020 01 15; 26(2):344-353.
View in: PubMed

Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 01; 20(1):8-17.e16.
View in: PubMed

HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074. PLoS One. 2019; 14(10):e0223829.
View in: PubMed

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
View in: PubMed

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020 03; 55(3):485-495.
View in: PubMed

Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile. Br J Haematol. 2020 02; 188(4):483-485.
View in: PubMed

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 08 22; 381(8):727-738.
View in: PubMed

Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs. AIDS Behav. 2019 Aug; 23(8):2101-2108.
View in: PubMed

Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Aliment Pharmacol Ther. 2019 08; 50(4):442-453.
View in: PubMed

Towards a better understanding of monoclonal gammopathy of renal significance. Br J Haematol. 2019 09; 186(5):653-654.
View in: PubMed

Validation of HIV-infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Med. 2019 09; 20(8):567-570.
View in: PubMed

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 06; 20(6):781-794.
View in: PubMed

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. Eur J Haematol. 2019 Jun; 102(6):494-503.
View in: PubMed

A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma. Clin Adv Hematol Oncol. 2019 May; 17 Suppl 9(5):2-8.
View in: PubMed

Correction: Dual Inhibition of Canonical and Noncanonical NF-?B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clin Cancer Res. 2019 May 01; 25(9):2938.
View in: PubMed

Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial). BMJ Open Gastroenterol. 2019; 6(1):e000290.
View in: PubMed

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2019 Apr; 33(4):1058-1059.
View in: PubMed

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. Br J Haematol. 2019 08; 186(3):e35-e39.
View in: PubMed

Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39.
View in: PubMed

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019 03 20; 9(4):37.
View in: PubMed

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226.
View in: PubMed

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019 07 11; 134(2):123-133.
View in: PubMed

The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction. 2019 06; 114(6):1113-1122.
View in: PubMed

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149.
View in: PubMed

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplant. 2019 12; 54(12):1951-1962.
View in: PubMed

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. AIDS. 2019 02 01; 33(2):237-246.
View in: PubMed

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019 07; 33(7):1736-1746.
View in: PubMed

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018 12 01; 4(12):e183267.
View in: PubMed

Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geriatr Oncol. 2019 05; 10(3):486-489.
View in: PubMed

The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052.
View in: PubMed

Ixazomib for the treatment of multiple myeloma. Expert Opin Pharmacother. 2018 Dec; 19(17):1949-1968.
View in: PubMed

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 12; 19(12):1641-1653.
View in: PubMed

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 11 09; 8(11):109.
View in: PubMed

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 11 08; 379(19):1811-1822.
View in: PubMed

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
View in: PubMed

An inhibitor of proteasome ß2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv. 2018 10 09; 2(19):2443-2451.
View in: PubMed

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
View in: PubMed

Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis. J Int AIDS Soc. 2018 10; 21(10):e25195.
View in: PubMed

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2018 10; 32(10):2305.
View in: PubMed

Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. Case Rep Hematol. 2018; 2018:3029650.
View in: PubMed

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 12 06; 132(23):2456-2464.
View in: PubMed

Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer. 2019 Feb; 17(1):58-64.e1.
View in: PubMed

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 10 15; 124(20):4032-4043.
View in: PubMed

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018 09 01; 392(10149):747-759.
View in: PubMed

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438.
View in: PubMed

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):137-144.
View in: PubMed

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
View in: PubMed

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018 08 28; 91(9):403-413.
View in: PubMed

Maintenance and continuous therapy for multiple myeloma. Expert Rev Anticancer Ther. 2018 08; 18(8):751-764.
View in: PubMed

How I treat the young patient with multiple myeloma. Blood. 2018 09 13; 132(11):1114-1124.
View in: PubMed

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123.
View in: PubMed

The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018 06 26; 2(12):1495-1509.
View in: PubMed

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br J Haematol. 2018 07; 182(2):231-244.
View in: PubMed

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; 65(10):e27269.
View in: PubMed

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018 08; 182(4):495-503.
View in: PubMed

Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. J Med Econ. 2018 Aug; 21(8):793-798.
View in: PubMed

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after =2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. Br J Haematol. 2018 06; 181(5):628-636.
View in: PubMed

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018 06; 181(6):816-827.
View in: PubMed

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):433-446.
View in: PubMed

Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018 08; 103(8):1380-1389.
View in: PubMed

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
View in: PubMed

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018 May 04.
View in: PubMed

Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):447-459.
View in: PubMed

Letter to the Editor: Response to Costa et al. Eur Neuropsychopharmacol. 2018 05; 28(5):658.
View in: PubMed

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2018 04; 57(4):529-538.
View in: PubMed

Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2018 Apr 01; 29(4):1074.
View in: PubMed

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
View in: PubMed

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
View in: PubMed

Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses. 2018 05; 34(5):421-429.
View in: PubMed

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia. 2018 09; 32(9):2032-2036.
View in: PubMed

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947.
View in: PubMed

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol. 2018 03; 180(6):821-830.
View in: PubMed

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2018 07; 53(7):942-945.
View in: PubMed

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. Br J Haematol. 2019 02; 184(3):475-479.
View in: PubMed

Ixazomib-induced cutaneous necrotizing vasculitis. Support Care Cancer. 2018 Jul; 26(7):2247-2250.
View in: PubMed

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Rev Clin Pharmacol. 2018 Feb; 11(2):113-124.
View in: PubMed

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2018 May; 14(11):1035-1047.
View in: PubMed

Optimizing therapy for del(17p) multiple myeloma. Oncotarget. 2017 Dec 15; 8(66):109859-109860.
View in: PubMed

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opin Pharmacother. 2017 Dec; 18(18):1975-1985.
View in: PubMed

The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017 12; 36(4):561-584.
View in: PubMed

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018 02; 32(2):252-262.
View in: PubMed

CD38 antibodies in multiple myeloma: back to the future. Blood. 2018 01 04; 131(1):13-29.
View in: PubMed

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. Br J Haematol. 2018 01; 180(1):41-51.
View in: PubMed

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 12 14; 130(24):2610-2618.
View in: PubMed

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017 12; 179(5):756-771.
View in: PubMed

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol. 2018 01; 180(2):271-275.
View in: PubMed

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Target Oncol. 2017 10; 12(5):643-654.
View in: PubMed

Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. Expert Rev Hematol. 2017 10; 10(10):933-939.
View in: PubMed

Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. Eur Neuropsychopharmacol. 2017 11; 27(11):1077-1089.
View in: PubMed

Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. Expert Rev Gastroenterol Hepatol. 2017 Oct; 11(10):885-898.
View in: PubMed

IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. Int J Dermatol. 2017 Oct; 56(10):1058-1060.
View in: PubMed

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med. 2017 Sep 19; 167(6):384-393.
View in: PubMed

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. J Blood Med. 2017; 8:107-121.
View in: PubMed

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
View in: PubMed

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol. 2017 Nov; 6(3):75-93.
View in: PubMed

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018 02; 53(2):138-145.
View in: PubMed

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017 10; 102(10):1767-1775.
View in: PubMed

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3279-3289.
View in: PubMed

Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 1: Focus on Investigations, Prophylaxis, and Specific Treatment. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1817-1825.
View in: PubMed

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 01; 35(25):2911-2918.
View in: PubMed

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 07 06; 10(1):137.
View in: PubMed

Drug Combinations with Transplantation for Myeloma. N Engl J Med. 2017 07 06; 377(1):93-94.
View in: PubMed

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 09 07; 130(10):1198-1204.
View in: PubMed

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep; 178(6):896-905.
View in: PubMed

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562.
View in: PubMed

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. JAMA Oncol. 2017 Jul 01; 3(7):980-988.
View in: PubMed

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. Br J Haematol. 2017 10; 179(1):66-74.
View in: PubMed

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. Eur J Haematol. 2017 Sep; 99(3):199-206.
View in: PubMed

Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Sep 12; 8(39):66641-66655.
View in: PubMed

Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 08.
View in: PubMed

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib. Nat Commun. 2017 06 08; 8:15761.
View in: PubMed

Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol. 2017 09; 178(5):756-763.
View in: PubMed

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017 12; 31(12):2695-2701.
View in: PubMed

IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751.
View in: PubMed

A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. Alcohol. 2017 08; 62:11-15.
View in: PubMed

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia. 2017 12; 31(12):2661-2669.
View in: PubMed

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017 08; 178(4):571-582.
View in: PubMed

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. Leukemia. 2017 12; 31(12):2652-2660.
View in: PubMed

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017 08; 178(4):547-560.
View in: PubMed

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017 07; 178(1):112-118.
View in: PubMed

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 04 06; 376(14):1311-1320.
View in: PubMed

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217.
View in: PubMed

Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017 04; 177(2):221-225.
View in: PubMed

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Marrow Transplant. 2017 Jun; 23(6):997-1004.
View in: PubMed

Deacetylase inhibitors: an advance in myeloma therapy? Expert Rev Hematol. 2017 Mar; 10(3):229-237.
View in: PubMed

Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017 02 01; 28(2):228-245.
View in: PubMed

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J Infect Dis. 2017 Jan 15; 215(2):238-246.
View in: PubMed

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319.
View in: PubMed

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017 07 01; 23(13):3307-3315.
View in: PubMed

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET. Mol Imaging. 2017 Jan-Dec; 16:1536012117736669.
View in: PubMed

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. Clin Pharmacol Ther. 2017 Jan; 101(1):81-88.
View in: PubMed

In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. Gastroenterology. 2017 04; 152(5):1068-1077.e4.
View in: PubMed

Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia. 2017 09; 31(9):1915-1921.
View in: PubMed

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341.
View in: PubMed

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacol Res. 2017 03; 117:185-191.
View in: PubMed

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13162-13167.
View in: PubMed

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia. 2017 05; 31(5):1059-1068.
View in: PubMed

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov; 3(11):e506-e515.
View in: PubMed

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 10 06; 375(14):1319-1331.
View in: PubMed

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016 Nov; 17(11):1569-1578.
View in: PubMed

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2016 10; 16(10):1291-301.
View in: PubMed

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 10 06; 128(14):1821-1828.
View in: PubMed

Point/Counterpoint: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma. One Size does not fit all. Oncology (Williston Park). 2016 08; 30(8):747-9.
View in: PubMed

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346.
View in: PubMed

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biol Blood Marrow Transplant. 2016 10; 22(10):1874-1882.
View in: PubMed

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5688-5695.
View in: PubMed

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016 12; 57(12):2833-2838.
View in: PubMed

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am J Hematol. 2016 Jun; 91(4):400-5.
View in: PubMed

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 07 07; 128(1):37-44.
View in: PubMed

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016 Jul; 51(7):906-12.
View in: PubMed

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016 Sep; 174(5):711-20.
View in: PubMed

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36.
View in: PubMed

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Apr 28; 374(17):1621-34.
View in: PubMed

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 11; 30(11):2187-2197.
View in: PubMed

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016 08; 174(3):397-409.
View in: PubMed

Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016 07; 22(7):1306-1312.
View in: PubMed

The Future of Myeloma Therapy: One Size Does Not Fit All. J Oncol Pract. 2016 Apr; 12(4):295-6.
View in: PubMed

Dual inhibition of oncogenic targets for B-cell malignancies. Lancet Oncol. 2016 05; 17(5):547-9.
View in: PubMed

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700.
View in: PubMed

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
View in: PubMed

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016 05 01; 34(13):1544-57.
View in: PubMed

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65.
View in: PubMed

Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol. 2016 Apr; 173(1):82-8.
View in: PubMed

Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016 Mar; 43(5):621-30.
View in: PubMed

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560.
View in: PubMed

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
View in: PubMed

Treatment of Relapsed/Refractory Multiple Myeloma. Cancer Treat Res. 2016; 169:169-194.
View in: PubMed

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016 05; 30(5):1005-17.
View in: PubMed

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50.
View in: PubMed

Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):e39-45.
View in: PubMed

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11; 127(6):713-21.
View in: PubMed

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016 Feb 11; 127(6):681-95.
View in: PubMed

Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847.
View in: PubMed

The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2?×?2 factorial randomised controlled trial. Health Technol Assess. 2015 Dec; 19(102):1-104.
View in: PubMed

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec; 2(12):e516-27.
View in: PubMed

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016; 9(1):35-48.
View in: PubMed

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. Br J Haematol. 2015 Dec; 171(5):798-812.
View in: PubMed

Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064. PLoS One. 2015; 10(10):e0140074.
View in: PubMed

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051.
View in: PubMed

Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res. 2015 Nov 01; 21(21):4767-73.
View in: PubMed

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016 Feb; 30(2):399-408.
View in: PubMed

Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015 Sep; 13(9):599-609.
View in: PubMed

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24; 373(13):1207-19.
View in: PubMed

Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. Biol Blood Marrow Transplant. 2016 Feb; 22(2):344-348.
View in: PubMed

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia. 2016 Feb; 30(2):379-89.
View in: PubMed

Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015 Aug 13; 126(7):921-2.
View in: PubMed

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33(26):2863-9.
View in: PubMed

Correction to: Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015; 15(9):1121.
View in: PubMed

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016 Mar; 30(3):761-4.
View in: PubMed

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46.
View in: PubMed

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015 Sep; 5(9):972-87.
View in: PubMed

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015; 15(7):737-48.
View in: PubMed

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13; 373(7):621-31.
View in: PubMed

Promising therapies in multiple myeloma. Blood. 2015 Jul 16; 126(3):300-10.
View in: PubMed

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
View in: PubMed

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
View in: PubMed

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J. 2015 May 15; 5:e312.
View in: PubMed

Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23; 372(17):1619-28.
View in: PubMed

Effect of water solvation on the lipophilicity of isomeric pyrimidine-carboxamides. Bioorg Med Chem. 2015 Jul 01; 23(13):3408-13.
View in: PubMed

Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Bone Marrow Transplant. 2015 Aug; 50(8):1024-9.
View in: PubMed

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Clin Cancer Res. 2015 Jun 15; 21(12):2660-2.
View in: PubMed

Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. . 2015 Apr 15; 68(5):554-61.
View in: PubMed

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015 Jul; 170(1):66-79.
View in: PubMed

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015 Sep; 29(9):1918-27.
View in: PubMed

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015 Jun; 50(6):781-9.
View in: PubMed

Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015 Jun; 55(6 Pt 2):1545-54.
View in: PubMed

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr; 90(4):314-9.
View in: PubMed

Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer. 2015 Sep; 23(9):2789-97.
View in: PubMed

Management of relapsed multiple myeloma after autologous stem cell transplant. Biol Blood Marrow Transplant. 2015 May; 21(5):793-8.
View in: PubMed

Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015 Jun; 29(6):1441-4.
View in: PubMed

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 03 26; 125(13):2068-74.
View in: PubMed

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol. 2015; 11(8):1153-68.
View in: PubMed

The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women. J Acquir Immune Defic Syndr. 2014 Dec 15; 67(5):573-5.
View in: PubMed

Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa. J Clin Virol. 2015 Jan; 62:75-9.
View in: PubMed

Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015 Jan; 12(1):42-54.
View in: PubMed

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
View in: PubMed

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec; 15(13):1503-1512.
View in: PubMed

Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). Value Health. 2014 Nov; 17(7):A617-8.
View in: PubMed

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov; 15(12):e538-48.
View in: PubMed

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014 Oct 17; 15:904.
View in: PubMed

Anti-tumor activities of selective HSP90a/ß inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia. 2015 Feb; 29(2):510-4.
View in: PubMed

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan; 100(1):100-6.
View in: PubMed

Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7.
View in: PubMed

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct; 15(11):1195-206.
View in: PubMed

Anaemia in pregnancy is associated with advanced HIV disease. PLoS One. 2014; 9(9):e106103.
View in: PubMed

Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014 Oct; 40(8):949-54.
View in: PubMed

Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):903-25.
View in: PubMed

The challenge of cross-trial comparisons using limited data. Haematologica. 2014 Aug; 99(8):e145-6.
View in: PubMed

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
View in: PubMed

Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies? Biol Blood Marrow Transplant. 2014 Aug; 20(8):1078-9.
View in: PubMed

Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. Drug Alcohol Depend. 2014 Sep 01; 142:139-45.
View in: PubMed

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 Aug 15; 74(16):4458-69.
View in: PubMed

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14; 124(7):1038-46.
View in: PubMed

Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014 Jul 10; 32(20):2125-32.
View in: PubMed

A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia. 2015 Jan; 29(1):218-29.
View in: PubMed

Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014 Oct; 167(1):127-31.
View in: PubMed

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014 Jun; 20(6):599-606.
View in: PubMed

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
View in: PubMed

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 2014 Jun; 99(6):1114-22.
View in: PubMed

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014 Apr 11; 4:e202.
View in: PubMed

Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in china and Thailand. Hepat Res Treat. 2014; 2014:296958.
View in: PubMed

Update on proteasome inhibitors in multiple myeloma. Clin Adv Hematol Oncol. 2014 Mar; 12(3):179-81.
View in: PubMed

Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014 Mar 01; 65(3):366-74.
View in: PubMed

Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. J Acquir Immune Defic Syndr. 2014 Mar 01; 65(3):268-77.
View in: PubMed

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15; 123(20):3128-38.
View in: PubMed

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014 02 21; 4:e182.
View in: PubMed

Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014 Apr; 23(4):445-52.
View in: PubMed

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar; 15(3):333-42.
View in: PubMed

The comprehensive clinical management of multiple myeloma and related-plasma cell disorders. Expert Rev Hematol. 2014 Feb; 7(1):1-3.
View in: PubMed

A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia. 2014 Aug; 28(8):1716-24.
View in: PubMed

Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):97-111.
View in: PubMed

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
View in: PubMed

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20; 32(6):587-600.
View in: PubMed

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32.
View in: PubMed

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.
View in: PubMed

Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014 Jan 01; 65(1):33-41.
View in: PubMed

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014 Jan 30; 123(5):632-9.
View in: PubMed

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30; 123(5):706-16.
View in: PubMed

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014 Mar; 28(3):525-42.
View in: PubMed

HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial. J Acquir Immune Defic Syndr. 2013 Nov 01; 64(3):299-306.
View in: PubMed

Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2013 Dec; 13(12):1731-40.
View in: PubMed

Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia. 2014 Feb; 28(2):457-60.
View in: PubMed

Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol. 2013 Oct; 40(5):537-48.
View in: PubMed

Evolving strategies in the initial treatment of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):592-601.
View in: PubMed

Clinical translation in multiple myeloma: from bench to bedside. Semin Oncol. 2013 Oct; 40(5):549-53.
View in: PubMed

Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
View in: PubMed

Percutaneous dilational and surgical tracheostomy in burn patients: incidence of complications and dysphagia. Burns. 2014 May; 40(3):436-42.
View in: PubMed

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013 Oct 10; 31(29):3696-703.
View in: PubMed

Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials. 2013 Aug 19; 14:262.
View in: PubMed

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 03; 122(14):2331-7.
View in: PubMed

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014 Mar; 28(3):680-9.
View in: PubMed

IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. Oncology (Williston Park). 2013 Aug; 27(8):803-4, 806.
View in: PubMed

Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013 Nov; 8(11):2007-17.
View in: PubMed

Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol. 2013 Sep; 49(9):977-983.
View in: PubMed

Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55.
View in: PubMed

Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):370-6.
View in: PubMed

Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol. 2013 Oct; 88 Suppl 1:S36-44.
View in: PubMed

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
View in: PubMed

Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab. 2013 Jul 01; 305(1):E50-8.
View in: PubMed

Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr. 2013 May 01; 63(1):1-8.
View in: PubMed

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65.
View in: PubMed

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 May; 71(5):1357-68.
View in: PubMed

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31.
View in: PubMed

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37.
View in: PubMed

Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J. 2013 Apr; 32(4):e164-9.
View in: PubMed

Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun; 19(6):858-9.
View in: PubMed

The prevalence of oesophageal eosinophilia and eosinophilic oesophagitis: a prospective study in unselected patients presenting to endoscopy. Aliment Pharmacol Ther. 2013 Apr; 37(8):825-32.
View in: PubMed

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood. 2013 Jan 31; 121(5):858.
View in: PubMed

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
View in: PubMed

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21; 121(8):1296-303.
View in: PubMed

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des. 2013; 19(4):734-44.
View in: PubMed

Hepatic sarcoidosis complicating treatment-naive viral hepatitis. World J Hepatol. 2012 Dec 27; 4(12):402-5.
View in: PubMed

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
View in: PubMed

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
View in: PubMed

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 01; 31(4):448-55.
View in: PubMed

Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013 Jan; 12(1):123-36.
View in: PubMed

New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66.
View in: PubMed

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr; 27(4):780-91.
View in: PubMed

Atypical presentation of miliary tuberculosis with hepatic involvement early after renal transplantation. Clin Gastroenterol Hepatol. 2013 Jul; 11(7):e52-3.
View in: PubMed

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90.
View in: PubMed

Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther. 2012 Dec; 36(11-12):1049-56.
View in: PubMed

Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Nov 29; 120(23):4513-6.
View in: PubMed

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 08; 120(19):3958-67.
View in: PubMed

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51.
View in: PubMed

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58.
View in: PubMed

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
View in: PubMed

Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012; 4:253-68.
View in: PubMed

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012 Aug; 3(4):253-65.
View in: PubMed

Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
View in: PubMed

Acute variceal bleeding in a man with coeliac disease. Gut. 2013 May; 62(5):740, 759.
View in: PubMed

How I treat plasma cell leukemia. Blood. 2012 Sep 20; 120(12):2376-89.
View in: PubMed

Dual inhibition of canonical and noncanonical NF-?B pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012 Sep 01; 18(17):4669-81.
View in: PubMed

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87.
View in: PubMed

Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. J Clin Oncol. 2012 Jul 10; 30(20):e175-9.
View in: PubMed

Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol. 2012 Jun; 5(3):291-302.
View in: PubMed

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80.
View in: PubMed

Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012 Aug 02; 120(5):947-59.
View in: PubMed

Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. J Med Chem. 2012 May 24; 55(10):4728-39.
View in: PubMed

Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
View in: PubMed

Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012 Jul; 89(1):16-27.
View in: PubMed

Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May; 8(5):623-33.
View in: PubMed

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012 May; 26(5):1153.
View in: PubMed

Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81.
View in: PubMed

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31.
View in: PubMed

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012 Sep; 26(9):1185-93.
View in: PubMed

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10; 119(19):4375-82.
View in: PubMed

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
View in: PubMed

Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
View in: PubMed

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012 Mar 22; 119(12):2764-7.
View in: PubMed

Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
View in: PubMed

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
View in: PubMed

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 01; 30(16):1960-5.
View in: PubMed

IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 Mar 29; 119(13):3003-15.
View in: PubMed

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther. 2012 Apr; 11(4):942-51.
View in: PubMed

Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr; 26(4):595-608.
View in: PubMed

Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Jan 21; 379(9812):221-8.
View in: PubMed

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
View in: PubMed

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011 Nov; 10(11):2034-42.
View in: PubMed

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

Persistent abdominal pain and pyrexia after combined radiofrequency ablation and TACE. Gastroenterology. 2011 Dec; 141(6):1976, 2277.
View in: PubMed

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
View in: PubMed

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem. 2011 Nov 10; 54(21):7693-704.
View in: PubMed

Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
View in: PubMed

A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics Clin Appl. 2011 Oct; 5(9-10):551.
View in: PubMed

Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol. 2011 Dec; 155(5):588-98.
View in: PubMed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
View in: PubMed

An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy. 2011 Sep; 3(9):1033-40.
View in: PubMed

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011 Dec; 52(12):2308-15.
View in: PubMed

Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. Int J Drug Policy. 2012 Mar; 23(2):162-5.
View in: PubMed

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57.
View in: PubMed

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011 Nov; 96(11):1662-9.
View in: PubMed

Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011 Sep; 154(6):745-54.
View in: PubMed

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One. 2011; 6(7):e20226.
View in: PubMed

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
View in: PubMed

Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells. Clin Appl Thromb Hemost. 2012 Jan-Feb; 18(1):79-86.
View in: PubMed

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15; 17(16):5311-21.
View in: PubMed

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica. 2011 Aug; 96(8):1170-9.
View in: PubMed

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
View in: PubMed

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
View in: PubMed

A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2011 May 20; 29(15_suppl):8075.
View in: PubMed

Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study. J Clin Oncol. 2011 May 20; 29(15_suppl):8014.
View in: PubMed

Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. J Clin Oncol. 2011 May 20; 29(15_suppl):8012.
View in: PubMed

PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS227.
View in: PubMed

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43.
View in: PubMed

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40.
View in: PubMed

Comfort care in burns: the Burn Modified Liverpool Care Pathway (BM-LCP). Burns. 2011 Sep; 37(6):981-5.
View in: PubMed

Multiple myeloma and amyloidosis: an evolving treatment paradigm toward the goal of tailored therapy. J Clin Oncol. 2011 May 10; 29(14):1801-2.
View in: PubMed

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May 10; 29(14):1916-23.
View in: PubMed

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011 May 26; 117(21):5692-700.
View in: PubMed

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011 May; 86(5):372-84.
View in: PubMed

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 09; 117(23):6063-73.
View in: PubMed

Hematology: Setting the standard for newly diagnosed multiple myeloma. Nat Rev Clin Oncol. 2011 May; 8(5):255-6.
View in: PubMed

Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011 Mar 15; 17(6):1264-77.
View in: PubMed

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011 Apr; 153(2):212-21.
View in: PubMed

Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics. 2011 Mar; 21(3):121-9.
View in: PubMed

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar; 11(3):254-84.
View in: PubMed

A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011 Apr; 11(8):1391-402.
View in: PubMed

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
View in: PubMed

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19.
View in: PubMed

Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther. 2011 Apr; 33(7):829-36.
View in: PubMed

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5.
View in: PubMed

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60.
View in: PubMed

Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):17-22.
View in: PubMed

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
View in: PubMed

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79.
View in: PubMed

Multiple myeloma. Annu Rev Med. 2011; 62:249-64.
View in: PubMed

Hematology: Bortezomib and dexamethasone induction for multiple myeloma. Nat Rev Clin Oncol. 2011 Jan; 8(1):8-10.
View in: PubMed

A new standard of care in newly diagnosed multiple myeloma. Lancet. 2010 Dec 18; 376(9758):2043-4.
View in: PubMed

Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. Clin Chim Acta. 2011 Mar 18; 412(7-8):562-8.
View in: PubMed

Improving the therapeutic index in myeloma. Blood. 2010 Dec 02; 116(23):4733-4.
View in: PubMed

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011 Jan; 86(1):23-31.
View in: PubMed

Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. Lancet Oncol. 2010 Nov; 11(11):1014-6.
View in: PubMed

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
View in: PubMed

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
View in: PubMed

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 02; 116(23):4906-15.
View in: PubMed

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
View in: PubMed

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010 Nov 11; 116(19):3743-50.
View in: PubMed

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; 150(4):438-45.
View in: PubMed

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37.
View in: PubMed

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
View in: PubMed

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010 Jun 15; 16(12):3260-9.
View in: PubMed

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6.
View in: PubMed

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8.
View in: PubMed

Kidney disease associated with plasma cell dyscrasias. Blood. 2010 Sep 02; 116(9):1397-404.
View in: PubMed

The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
View in: PubMed

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun; 24(6):1121-7.
View in: PubMed

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
View in: PubMed

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
View in: PubMed

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood. 2010 Jul 29; 116(4):593-602.
View in: PubMed

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
View in: PubMed

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010 May 01; 28(13):2259-66.
View in: PubMed

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
View in: PubMed

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5.
View in: PubMed

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49.
View in: PubMed

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
View in: PubMed

Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5.
View in: PubMed

The evolution and impact of therapy in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S1-6.
View in: PubMed

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17.
View in: PubMed

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
View in: PubMed

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010 Feb; 8 Suppl 1:S4-S12.
View in: PubMed

Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
View in: PubMed

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 01; 16(3):1033-41.
View in: PubMed

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22; 29(16):2325-36.
View in: PubMed

Assembly of 500,000 inter-specific catfish expressed sequence tags and large scale gene-associated marker development for whole genome association studies. Genome Biol. 2010 Jan 22; 11(1):R8.
View in: PubMed

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 2010 Jul; 95(7):1144-9.
View in: PubMed

The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Blood Coagul Fibrinolysis. 2009 Dec; 20(8):627-34.
View in: PubMed

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.
View in: PubMed

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010 Jan 28; 115(4):834-45.
View in: PubMed

How I treat multiple myeloma in younger patients. Blood. 2009 Dec 24; 114(27):5436-43.
View in: PubMed

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009 Dec 20; 27(36):6086-93.
View in: PubMed

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
View in: PubMed

Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
View in: PubMed

Hematology: Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol. 2009 Oct; 6(10):565-6.
View in: PubMed

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
View in: PubMed

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68.
View in: PubMed

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.
View in: PubMed

The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
View in: PubMed

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13.
View in: PubMed

Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
View in: PubMed

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2009 Nov; 147(4):531-4.
View in: PubMed

Use of defibrotide in the treatment and prevention of veno-occlusive disease. Expert Rev Hematol. 2009 Aug; 2(4):365-76.
View in: PubMed

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
View in: PubMed

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35.
View in: PubMed

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Oct; 23(10):1904-12.
View in: PubMed

Multiple myeloma. Lancet. 2009 Jul 25; 374(9686):324-39.
View in: PubMed

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
View in: PubMed

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
View in: PubMed

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Oct; 23(10):1716-30.
View in: PubMed

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23; 114(4):772-8.
View in: PubMed

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009 Jul; 146(2):164-70.
View in: PubMed

Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. J Clin Oncol. 2009 May 20; 27(15_suppl):8503.
View in: PubMed

Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):8535.
View in: PubMed

Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol. 2009 May 20; 27(15_suppl):8536.
View in: PubMed

Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):e14539.
View in: PubMed

Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial. J Clin Oncol. 2009 May 20; 27(15_suppl):8517.
View in: PubMed

Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM). J Clin Oncol. 2009 May 20; 27(15_suppl):8505.
View in: PubMed

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study. J Clin Oncol. 2009 May 20; 27(15_suppl):8586.
View in: PubMed

Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM). J Clin Oncol. 2009 May 20; 27(15_suppl):8601.
View in: PubMed

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52.
View in: PubMed

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
View in: PubMed

Maximizing the clinical benefit of novel therapies in multiple myeloma. Oncology (Williston Park). 2009 Apr 30; 23(5):415-6, 419.
View in: PubMed

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
View in: PubMed

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36.
View in: PubMed

Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar; 14(1):99-127.
View in: PubMed

Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar; 67(3):593-601.
View in: PubMed

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009 Feb 15; 15(4):1210-21.
View in: PubMed

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903.
View in: PubMed

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009 May; 23(5):961-70.
View in: PubMed

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb; 23(2):215-24.
View in: PubMed

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008 Nov; 143(4):511-9.
View in: PubMed

Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol. 2008 Oct; 6(10):755-60.
View in: PubMed

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov; 143(4):537-40.
View in: PubMed

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31.
View in: PubMed

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
View in: PubMed

Identification of Helicobacter pylori infected patients, using administrative data. Aliment Pharmacol Ther. 2008 Dec 01; 28(11-12):1309-16.
View in: PubMed

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28; 359(9):906-17.
View in: PubMed

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008 Oct 10; 26(29):4784-90.
View in: PubMed

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.
View in: PubMed

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008 Nov 15; 112(10):4343-52.
View in: PubMed

Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1166-74.
View in: PubMed

The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
View in: PubMed

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(1):46-53.
View in: PubMed

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008 Oct; 22(10):1925-32.
View in: PubMed

Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
View in: PubMed

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.
View in: PubMed

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5.
View in: PubMed

The complete genome sequence of Moorella thermoacetica (f. Clostridium thermoaceticum). Environ Microbiol. 2008 Oct; 10(10):2550-73.
View in: PubMed

The evolving treatment paradigm of multiple myeloma: From past to present and future. Turk J Haematol. 2008 Jun 05; 25(2):60-70.
View in: PubMed

Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2008 May 20; 26(15_suppl):8546.
View in: PubMed

Inhibition of fatty acid synthase induces anti-tumor effect in multiple myeloma. J Clin Oncol. 2008 May 20; 26(15_suppl):19522.
View in: PubMed

Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2008 May 20; 26(15_suppl):8525.
View in: PubMed

Effects of defibrotide on tumour adhesion and invasion in multiple myeloma, breast cancer and renal cell cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):8600.
View in: PubMed

Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. J Clin Oncol. 2008 May 20; 26(15_suppl):8524.
View in: PubMed

Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008 May 20; 26(15_suppl):8545.
View in: PubMed

Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. J Clin Oncol. 2008 May 20; 26(15_suppl):8520.
View in: PubMed

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008 Jul 01; 26(19):3196-203.
View in: PubMed

Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina). Nat Biotechnol. 2008 May; 26(5):553-60.
View in: PubMed

Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jun; 105(6):e1-4.
View in: PubMed

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
View in: PubMed

Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008 May; 141(5):659-71.
View in: PubMed

The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus. Aliment Pharmacol Ther. 2008 Jun; 27(12):1293-9.
View in: PubMed

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):502-7.
View in: PubMed

Re: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2008 Mar 05; 100(5):373.
View in: PubMed

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
View in: PubMed

The myeloma landscape in 2008. Clin Adv Hematol Oncol. 2008 Feb; 6(2 Suppl 2):1-12; quiz 15-6.
View in: PubMed

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008 Feb; 4(1):129-36.
View in: PubMed

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008 Apr; 22(4):842-9.
View in: PubMed

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb; 22(2):414-23.
View in: PubMed

The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007 Dec; 20(4):597-612.
View in: PubMed

From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):797-816.
View in: PubMed

Management of relapsed and relapsed refractory myeloma. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1175-215, x.
View in: PubMed

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii.
View in: PubMed

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64.
View in: PubMed

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008 Feb; 41(3):229-37.
View in: PubMed

The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008 Feb 01; 27(3):274-82.
View in: PubMed

Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9.
View in: PubMed

Novel therapies in myeloma. Curr Opin Hematol. 2007 Nov; 14(6):609-15.
View in: PubMed

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007 Oct 15; 13(20):6162-7.
View in: PubMed

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63.
View in: PubMed

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37.
View in: PubMed

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91.
View in: PubMed

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol. 2007 Sep; 82(9):831-3.
View in: PubMed

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15; 110(10):3557-60.
View in: PubMed

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007 Aug; 7(8):585-98.
View in: PubMed

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68.
View in: PubMed

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007 Jul 01; 13(13):3771-5.
View in: PubMed

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia. 2007 Nov; 21(11):2358-9.
View in: PubMed

Legumes symbioses: absence of Nod genes in photosynthetic bradyrhizobia. Science. 2007 Jun 01; 316(5829):1307-12.
View in: PubMed

Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
View in: PubMed

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost. 2007 Jun; 33(4):373-88.
View in: PubMed

New drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89.
View in: PubMed

Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5.
View in: PubMed

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
View in: PubMed

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007 Jun; 137(5):429-35.
View in: PubMed

Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther. 2007 Apr 15; 25(8):913-24.
View in: PubMed

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2007 Apr; 7(4):551-66.
View in: PubMed

Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007 Mar; 12(1):155-63.
View in: PubMed

Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway. Leukemia. 2007 Mar; 21(3):535-40.
View in: PubMed

The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw. 2007 Feb; 5(2):149-62.
View in: PubMed

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96.
View in: PubMed

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007 Jan 20; 25(3):247-56.
View in: PubMed

Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology. 2007 Mar; 52(4):1095-105.
View in: PubMed

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007 Jan; 92(1):95-100.
View in: PubMed

The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
View in: PubMed

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 Apr 15; 109(8):3177-88.
View in: PubMed

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol. 2007 Feb; 136(3):414-23.
View in: PubMed

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006 Dec 06; 296(21):2558-60.
View in: PubMed

Bortezomib as an antitumor agent. Curr Pharm Biotechnol. 2006 Dec; 7(6):441-8.
View in: PubMed

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007 Mar 15; 109(6):2604-6.
View in: PubMed

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan; 21(1):151-7.
View in: PubMed

Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma. 2006 Nov; 7(3):233-5.
View in: PubMed

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
View in: PubMed

Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1.
View in: PubMed

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7.
View in: PubMed

Comparative genomics of the lactic acid bacteria. Proc Natl Acad Sci U S A. 2006 Oct 17; 103(42):15611-6.
View in: PubMed

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007 Apr 05; 26(16):2374-80.
View in: PubMed

Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006 Oct; 7(10):1341-7.
View in: PubMed

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94.
View in: PubMed

Recent advances in the treatment of Multiple Myeloma. Curr Pharm Biotechnol. 2006 Oct; 7(5):381-93.
View in: PubMed

The genome of black cottonwood, Populus trichocarpa (Torr. & Gray). Science. 2006 Sep 15; 313(5793):1596-604.
View in: PubMed

Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006 Aug; 6(8):1165-73.
View in: PubMed

International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep; 20(9):1467-73.
View in: PubMed

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64.
View in: PubMed

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82.
View in: PubMed

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul; 91(7):929-34.
View in: PubMed

Phase I trial of chir-258 in multiple myeloma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):17502.
View in: PubMed

Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3066.
View in: PubMed

Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7546.
View in: PubMed

Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4510.
View in: PubMed

Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7504.
View in: PubMed

Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):524.
View in: PubMed

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73.
View in: PubMed

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20.
View in: PubMed

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol. 2006 May; 4(5):1; discussion 8; suppl 13.
View in: PubMed

Optimizing bortezomib treatment in patients with relapsed multiple myeloma. Clin Adv Hematol Oncol. 2006 May; 4(5):4-5; discussion 8; suppl 13.
View in: PubMed

Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation. Oncology (Williston Park). 2006 May; 20(6):633-8.
View in: PubMed

Pathways of carbon assimilation and ammonia oxidation suggested by environmental genomic analyses of marine Crenarchaeota. PLoS Biol. 2006 Apr; 4(4):e95.
View in: PubMed

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006 Mar 15; 106(6):1316-9.
View in: PubMed

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704.
View in: PubMed

Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs. 2006 Feb; 15(2):171-9.
View in: PubMed

Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006 Feb; 132(4):385-97.
View in: PubMed

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62.
View in: PubMed

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 01; 66(1):184-91.
View in: PubMed

Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006; 57:33-47.
View in: PubMed

Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006; 16(1):105-14.
View in: PubMed

Resources for genetic and genomic studies of Xenopus. Methods Mol Biol. 2006; 322:1-16.
View in: PubMed

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2006 Jan 20; 24(3):334-6.
View in: PubMed

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
View in: PubMed

New treatments for multiple myeloma. Oncology (Williston Park). 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7.
View in: PubMed

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Nov 15; 104(10):2141-8.
View in: PubMed

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19.
View in: PubMed

Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100.
View in: PubMed

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Semin Hematol. 2005 Oct; 42(4 Suppl 4):S9-15.
View in: PubMed

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005 Oct; 131(1):71-3.
View in: PubMed

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8.
View in: PubMed

Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005 Sep 10; 23(26):6345-50.
View in: PubMed

Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8.
View in: PubMed

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84.
View in: PubMed

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005 Dec 01; 106(12):3777-84.
View in: PubMed

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005 Nov 01; 106(9):2977-81.
View in: PubMed

Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005 Jul 07; 353(1):99-102; discussion 99-102.
View in: PubMed

Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia. 2005 Jul; 19(7):1253-61.
View in: PubMed

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906.
View in: PubMed

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16; 352(24):2487-98.
View in: PubMed

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
View in: PubMed

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8567-72.
View in: PubMed

Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): Results from APEX study. J Clin Oncol. 2005 Jun; 23(16_suppl):6535.
View in: PubMed

Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma. J Clin Oncol. 2005 Jun; 23(16_suppl):3122.
View in: PubMed

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma. J Clin Oncol. 2005 Jun; 23(16_suppl):6533.
View in: PubMed

Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):3056.
View in: PubMed

Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. J Clin Oncol. 2005 Jun; 23(16_suppl):6501.
View in: PubMed

Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity. J Clin Oncol. 2005 Jun; 23(16_suppl):6610.
View in: PubMed

Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):6682.
View in: PubMed

Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Rev Anticancer Ther. 2005 Jun; 5(3):465-76.
View in: PubMed

How to be moderately halophilic with broad salt tolerance: clues from the genome of Chromohalobacter salexigens. Extremophiles. 2005 Aug; 9(4):275-9.
View in: PubMed

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005 Sep 01; 106(5):1794-800.
View in: PubMed

New therapies for the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2005 May; 3(5):345-6.
View in: PubMed

Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. J Clin Oncol. 2005 May 01; 23(13):3138-40.
View in: PubMed

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9.
View in: PubMed

Proteasome inhibitor therapy in multiple myeloma. . 2005 Apr; 4(4):686-92.
View in: PubMed

Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol. 2005 Apr; 1(2):161-71.
View in: PubMed

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 Mar 15; 103(6):1195-200.
View in: PubMed

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200.
View in: PubMed

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6.
View in: PubMed

Proteasome inhibition in the treatment of cancer. . 2005 Feb; 4(2):290-6.
View in: PubMed

Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005 Jan 20; 23(3):630-9.
View in: PubMed

Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83.
View in: PubMed

Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):619-34.
View in: PubMed

Proteasome inhibitors as therapeutics. Essays Biochem. 2005; 41:205-18.
View in: PubMed

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203.
View in: PubMed

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-2004. A 40-year-old man with a large tumor of the skull. N Engl J Med. 2004 Dec 16; 351(25):2637-45.
View in: PubMed

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53.
View in: PubMed

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
View in: PubMed

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004 Nov 15; 10(22):7540-6.
View in: PubMed

Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract. 2004 Nov; 58(11):1033-41.
View in: PubMed

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6.
View in: PubMed

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct; 127(2):165-72.
View in: PubMed

The DNA sequence and comparative analysis of human chromosome 5. Nature. 2004 Sep 16; 431(7006):268-74.
View in: PubMed

A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2004 Sep; 10(9):635-44.
View in: PubMed

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
View in: PubMed

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood. 2005 Mar 01; 105(5):2235-8.
View in: PubMed

Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6511.
View in: PubMed

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol. 2004 Aug 15; 22(16):3212-4.
View in: PubMed

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul; 79(7):875-82.
View in: PubMed

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004 Nov 01; 104(9):2886-92.
View in: PubMed

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66.
View in: PubMed

An update of novel therapeutic approaches for multiple myeloma. Curr Treat Options Oncol. 2004 Jun; 5(3):227-38.
View in: PubMed

Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Rev Clin Exp Hematol. 2004 Jun 01; 8(1):E3.
View in: PubMed

A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother. 2004 Jun; 5(6):1321-31.
View in: PubMed

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
View in: PubMed

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
View in: PubMed

The DNA sequence and biology of human chromosome 19. Nature. 2004 Apr 01; 428(6982):529-35.
View in: PubMed

Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry. 2004 Feb 10; 43(5):1254-63.
View in: PubMed

Closing the gaps on human chromosome 19 revealed genes with a high density of repetitive tandemly arrayed elements. Genome Res. 2004 Feb; 14(2):239-46.
View in: PubMed

Proteasome inhibition in hematologic malignancies. Ann Med. 2004; 36(4):304-14.
View in: PubMed

Multiple myeloma. Hematology Am Soc Hematol Educ Program. 2004; 237-56.
View in: PubMed

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66.
View in: PubMed

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36.
View in: PubMed

Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003 Dec; 32(12):1145-51.
View in: PubMed

Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene. 2003 Nov 27; 22(54):8797-801.
View in: PubMed

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004 May 01; 103(9):3474-9.
View in: PubMed

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93.
View in: PubMed

Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003 Nov; 10(6):451-62.
View in: PubMed

Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol. 2003 Oct; 1(10):596-600.
View in: PubMed

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 Oct 01; 63(19):6187-94.
View in: PubMed

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90.
View in: PubMed

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8.
View in: PubMed

Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003 Sep-Oct; 10(5):361-9.
View in: PubMed

Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. Oncology (Williston Park). 2003 Aug; 17(8):1063-5.
View in: PubMed

Novel therapeutic approaches for multiple myeloma. Immunol Rev. 2003 Aug; 194:164-76.
View in: PubMed

A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17.
View in: PubMed

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
View in: PubMed

Mechanisms of thermal adaptation revealed from the genomes of the Antarctic Archaea Methanogenium frigidum and Methanococcoides burtonii. Genome Res. 2003 Jul; 13(7):1580-8.
View in: PubMed

Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol. 2003 Jun; 7(2):191-204.
View in: PubMed

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8.
View in: PubMed

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
View in: PubMed

Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev. 2003 May; 29 Suppl 1:33-9.
View in: PubMed

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6.
View in: PubMed

Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003 Aug 15; 102(4):1435-42.
View in: PubMed

Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12.
View in: PubMed

Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.
View in: PubMed

Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD. Pathophysiol Haemost Thromb. 2003; 33 Suppl 1:50-3.
View in: PubMed

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.
View in: PubMed

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14.
View in: PubMed

Genetic and genomic tools for Xenopus research: The NIH Xenopus initiative. Dev Dyn. 2002 Dec; 225(4):384-91.
View in: PubMed

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
View in: PubMed

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7.
View in: PubMed

Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
View in: PubMed

Impact of supervision and self-assessment on doctor-patient communication in rural Mexico. Int J Qual Health Care. 2002 Oct; 14(5):359-67.
View in: PubMed

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4.
View in: PubMed

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94.
View in: PubMed

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15; 101(2):703-5.
View in: PubMed

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000.
View in: PubMed

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
View in: PubMed

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
View in: PubMed

Novel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1.
View in: PubMed

Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. . 2002 Aug; 1(10):851-60.
View in: PubMed

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43.
View in: PubMed

Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82.
View in: PubMed

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
View in: PubMed

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
View in: PubMed

High-Throughput Protein Expression and Purification for Proteomics Research. ScientificWorldJournal. 2002; 2:146-147.
View in: PubMed

Thalidomide in multiple myeloma. Biomed Pharmacother. 2002 May; 56(3):115-28.
View in: PubMed

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. . 2002 May; 1(7):539-44.
View in: PubMed

NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47.
View in: PubMed

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58.
View in: PubMed

Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002 Feb; 29 Suppl 1:S14-7.
View in: PubMed

The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant. 2002; 8(4):198-205.
View in: PubMed

Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant. 2002; 8(6):326-33.
View in: PubMed

Randomized controlled trial to investigate influence of the fluid challenge on duration of hospital stay and perioperative morbidity in patients with hip fractures. Br J Anaesth. 2002 Jan; 88(1):65-71.
View in: PubMed

Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002; 53:629-57.
View in: PubMed

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001 Dec; 15(12):1950-61.
View in: PubMed

Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001 Dec; 28(6):607-12.
View in: PubMed

Client communication behaviors with health care providers in Indonesia. Patient Educ Couns. 2001 Oct; 45(1):59-68.
View in: PubMed

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplant. 2001 Sep; 28(5):447-54.
View in: PubMed

Species specificity of amidine-based urokinase inhibitors. Biochemistry. 2001 Aug 07; 40(31):9125-31.
View in: PubMed

Acute liver failure as the initial manifestation of acute leukaemia. Liver. 2001 Aug; 21(4):287-92.
View in: PubMed

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001 Aug 01; 98(3):795-804.
View in: PubMed

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001 Jul 27; 20(33):4519-27.
View in: PubMed

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001 Jul 15; 98(2):428-35.
View in: PubMed

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 01; 98(1):210-6.
View in: PubMed

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001 Apr 01; 61(7):3071-6.
View in: PubMed

Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15; 409(6822):860-921.
View in: PubMed

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; 27(3):269-78.
View in: PubMed

Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001; 106(1-2):57-68.
View in: PubMed

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 01; 96(9):2943-50.
View in: PubMed

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 Sep; 109(4):267-76.
View in: PubMed

Discovery of a novel, paternally expressed ubiquitin-specific processing protease gene through comparative analysis of an imprinted region of mouse chromosome 7 and human chromosome 19q13.4. Genome Res. 2000 Aug; 10(8):1138-47.
View in: PubMed

Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76.
View in: PubMed

Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen. Aliment Pharmacol Ther. 2000 May; 14(5):543-9.
View in: PubMed

Proximal median neuropathy secondary to humeral neck fracture. Muscle Nerve. 2000 Mar; 23(3):426-9.
View in: PubMed

Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res. 2000 Feb; 6(2):434-42.
View in: PubMed

Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46.
View in: PubMed

Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95.
View in: PubMed

The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol. 1999 Dec; 107(3):485-93.
View in: PubMed

The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant. 1999 Nov; 24(9):939-45.
View in: PubMed

Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41.
View in: PubMed

Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone. 1999 May; 24(5 Suppl):81S-85S.
View in: PubMed

Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol. 1999 Apr; 17(4):1175.
View in: PubMed

Nerve growth factor and proprotein convertases furin and PC7 in transected sciatic nerves and in nerve segments cultured in conditioned media: their presence in Schwann cells, macrophages, and smooth muscle cells. J Comp Neurol. 1999 Jan 25; 403(4):471-85.
View in: PubMed

Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma. 1998 Oct; 31(3-4):267-77.
View in: PubMed

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998 Sep; 4(9):2027-37.
View in: PubMed

Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998 Aug 01; 83(3):409-14.
View in: PubMed

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44.
View in: PubMed

Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis. 1998 Aug; 19(11):2031-42.
View in: PubMed

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998 Jul; 9(7):711-6.
View in: PubMed

High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998 Mar; 16(3):1000-7.
View in: PubMed

Making sense of asthma. Expert Opin Investig Drugs. 1997 Sep; 6(9):1143-7.
View in: PubMed

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997 Aug 08; 277(5327):805-8.
View in: PubMed

High levels of incorrect use of car seat belts and child restraints in Fife--an important and under-recognised road safety issue. Inj Prev. 1997 Mar; 3(1):17-22.
View in: PubMed

Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996 Nov; 14(11):2984-92.
View in: PubMed

Additive effects of extra cellular matrix proteins and platelet derived mitogens on human retinal pigment epithelial cell proliferation and contraction. Curr Eye Res. 1996 Jul; 15(7):739-48.
View in: PubMed

Ciliary neurotrophic factor, unlike nerve growth factor, supports neurite outgrowth but not synapse formation by adult Lymnaea neurons. J Neurobiol. 1996 Mar; 29(3):293-303.
View in: PubMed

Body experience differences of women with preterm labor. Matern Child Nurs J. 1996 Jan-Mar; 24(1):5-17.
View in: PubMed

Crescentic glomerulonephritis and eosinophilic interstitial infiltrates in a patient with hypereosinophilic syndrome. Postgrad Med J. 1995 Mar; 71(833):175-8.
View in: PubMed

Nucleotide sequencing of PCR products shows the presence of Coxsackie-B3 virus in endomyocardial biopsies from patients with myocarditis or dilated cardiomyopathy. Biochem Soc Trans. 1994 May; 22(2):176S.
View in: PubMed

Nonpenetrating trauma to the carotid artery: seven cases and a literature review. J Trauma. 1994 Feb; 36(2):265-72.
View in: PubMed

An observational study of car occupant restraint in Fife: impact of recent legislation. Public Health. 1993 Nov; 107(6):429-35.
View in: PubMed

Immunophenotypic and idiotypic characterisation of the leukaemic B-cells from patients with prolymphocytic leukaemia: evidence for a selective expression of immunoglobulin variable region (IGV) gene products. Leuk Res. 1993 Aug; 17(8):669-76.
View in: PubMed

Modulation and high frequency expression of autoantibody-associated cross-reactive idiotypes linked to the VHI subgroup in CD5-expressing B lymphocytes from patients with chronic lymphocytic leukaemia (B-CLL). Scand J Immunol. 1993 Jun; 37(6):673-9.
View in: PubMed

Rates of protein synthesis in different regions of the normotensive and hypertrophied heart in response to acute alcohol toxicity. Alcohol Alcohol. 1993 May; 28(3):297-310.
View in: PubMed

Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990 Nov; 87(22):8931-4.
View in: PubMed

A new biochemical engineering approach to the fractional precipitation of proteins. Biotechnol Bioeng. 1990 Aug 05; 36(4):354-66.
View in: PubMed

Oncogenic transformation by vrel requires an amino-terminal activation domain. Mol Cell Biol. 1990 Jun; 10(6):2840-7.
View in: PubMed

Stimulation of B-chronic lymphocytic leukemia populations by recombinant interleukin-4 and other defined growth-promoting agents. Leukemia. 1988 Mar; 2(3):165-70.
View in: PubMed

Mycobacterium tuberculosis antigen specific human T-cell lines are cytolytic to autologous antigen pulsed macrophages. Adv Exp Med Biol. 1988; 237:401-6.
View in: PubMed

An antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigen. Clin Exp Immunol. 1986 Jul; 65(1):112-9.
View in: PubMed

The incidence of B cell leukaemia and lymphopenia in B cell neoplasia in adults: a study using the Kiel classification of non-Hodgkin's lymphoma. Br J Cancer. 1983 Aug; 48(2):185-93.
View in: PubMed

Women's perceptions of change in relationships shared with children during pregnancy. Matern Child Nurs J. 1983; 12(2):75-88.
View in: PubMed

Unusual presentation of thyrocardiac disease. Lancet. 1971 Nov 27; 2(7735):1163-7.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1B07
Boston, MA 02215
Get Directions

Top